Nektar Therapeutics (NKTR) Tops Q3 EPS by 4c

November 3, 2016 4:47 PM EDT
Get Alerts NKTR Hot Sheet
Trade NKTR Now!
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Nektar Therapeutics (NASDAQ: NKTR) reported Q3 EPS of ($0.32), $0.04 better than the analyst estimate of ($0.36). Revenue for the quarter came in at $36.3 million versus the consensus estimate of $32.42 million.

For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories


Related Entities


Add Your Comment